Correlation Between Mineralys Therapeutics, and Syndax Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Syndax Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Syndax Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Syndax Pharmaceuticals, you can compare the effects of market volatilities on Mineralys Therapeutics, and Syndax Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Syndax Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Syndax Pharmaceuticals.

Diversification Opportunities for Mineralys Therapeutics, and Syndax Pharmaceuticals

0.56

Correlation Coefficient

Mineralys Therapeutics,  Syndax Pharmaceuticals

Very weak diversification

The 3 months correlation between Mineralys and Syndax is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Syndax Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Syndax Pharmaceuticals and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Syndax Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Syndax Pharmaceuticals has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Syndax Pharmaceuticals go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Syndax Pharmaceuticals

Given the investment horizon of 90 days Mineralys Therapeutics, Common is expected to generate 1.54 times more return on investment than Syndax Pharmaceuticals. However, Mineralys Therapeutics, is 1.54 times more volatile than Syndax Pharmaceuticals. It trades about 0.1 of its potential returns per unit of risk. Syndax Pharmaceuticals is currently generating about -0.24 per unit of risk. If you would invest  1,140  in Mineralys Therapeutics, Common on September 19, 2024 and sell it today you would earn a total of  95.00  from holding Mineralys Therapeutics, Common or generate 8.33% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Syndax Pharmaceuticals

Mineralys Therapeutics,

Risk-Adjusted Performance

2 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Syndax Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Syndax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Mineralys Therapeutics, and Syndax Pharmaceuticals

The main advantage of trading using opposite Mineralys Therapeutics, and Syndax Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Syndax Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Syndax Pharmaceuticals will offset losses from the drop in Syndax Pharmaceuticals' long position.

The idea behind Mineralys Therapeutics, Common and Syndax Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.